Disease Areas
Diabetes
Obesity
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Neurodegenerative Diseases
Haemophilia
Sickle Cell Disease
Primary Hyperoxaluria
Growth Hormone Disorders
Hormone Replacement Therapy
Congresses
Scientific Publications
IME
Search Science Hub
Register
Login
My Account
Welcome to Novo Nordisk Science Hub
Are you a healthcare professional?
No
Yes
Congresses
ENDO 2025
Real-world Weight Loss Observed With Semaglutide and Tirzepatide in Patients With Overweight or Obesity and Without Type 2 Diabetes
ENDO 2025
ENDO 2025
12 - 15 July 2025
Real-world Weight Loss Observed With Semaglutide And Tirzepatide In Patients With Overweight Or Obesity And Without Type 2 Diabetes
Authors
:
Carmen Ng
1
; Victoria Divino
1
; Julia Wang
1
; Joshua Toliver
1
; Marcio Buss
1
Affiliations
View Details
Hide Details
Download poster (.pdf)
Share
Copy link
{{pageUrl}}
Keywords
Obesity
Congress poster
GLP-1 RA
Semaglutide
RWE HEOR